Increase in prevalence seen during same period; narrowing of gap in incidence between White and Black, White and Hispanic from 2015 to 2021
FRIDAY, May 23, 2025 (HealthDay News) — From 2015 to 2021, there was a decrease in the incidence of dementia, but an increase in prevalence, according to a study published online May 20 in The BMJ.
Beau Blass, M.P.H., from Duke University School of Medicine in Durham, North Carolina, and colleagues examined the incidence and prevalence of dementia in a nationally representative cohort of U.S. Medicare beneficiaries in a population-based study.
The researchers documented 5,025,039 incident cases of dementia from 2015 to 2021. There was a decrease in the overall age and sex standardized incidence between 2015 and 2021, from 3.5 to 2.8 percent. During the same time, prevalence increased from 10.5 to 11.8 percent. Higher age standardized incidence was seen for male versus female beneficiaries in 2015 (3.5 versus 3.4 percent); the difference increased by 2021 (2.9 versus 2.6 percent; estimated difference-in-difference, 0.94). In 2015, incidence was highest for Black beneficiaries, followed by Hispanic and White beneficiaries (4.2, 3.7, and 3.4 percent, respectively); in 2021, incidence was 3.1, 2.8, and 2.6 percent for Black, White, and Hispanic beneficiaries, respectively, with the differences between White and Black and White and Hispanic beneficiaries narrowing from 2015 to 2021 (estimated difference-in-differences, 0.92 and 0.88, respectively).
“The burden of dementia was unequally distributed, with the highest incidence and prevalence of dementia among Black beneficiaries and those living in socioeconomically deprived neighborhoods,” the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Insurance Poses Barrier to Virtual Pulmonary Rehabilitation for COPD
Cortical Atrophy in Early-Onset Alzheimer Disease Signature Can Predict Progression to Dementia
Exercise Link to Dementia Varies by Physical Activity Domain
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings
Many With Atypical Alzheimer Disease Do Not Qualify for Anti-Amyloid Therapy
Subclinical Cardiac Dysfunction Linked to Neurodegeneration in APOE-ε4 Carriers
Study IDs Dementia Risk Factors in Those Older Than 90 Years